Satralizumab Market – Targeted Treatment for Neuromyelitis Optica Spectrum Disorder
The Satralizumab Market is associated with satralizumab, a monoclonal antibody that targets the interleukin-6 receptor. The medicine is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD) in eligible patients, according to applicable local approvals and prescribing guidance.
Current Market Landscape
The market is shaped by the need for therapies that reduce the risk of...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek